Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Theodorakis, M. J.
Right arrow Articles by Egan, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Theodorakis, M. J.
Right arrow Articles by Egan, J. M.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Care 27:1692-1698, 2004
© 2004 by the American Diabetes Association, Inc.


Pathophysiology/Complications
Original Article

Elevated Plasma Glucose-Dependent Insulinotropic Polypeptide Associates With Hyperinsulinemia in Impaired Glucose Tolerance

Michael J. Theodorakis, MD, PHD, Olga Carlson, PHD, Denis C. Muller, MS and Josephine M. Egan, MD

From the Diabetes Section, National Institute on Aging, National Institutes of Health, Bethesda, Maryland

Address correspondence and reprint requests to Josephine M. Egan, MD, Diabetes Section, NIA, NIH, 5600 Nathan Shock Dr., GRC-2B02, Baltimore, MD 21224. E-mail: eganj{at}vax.grc.nia.nih.gov

OBJECTIVE—The role of gut-derived incretin, glucose-dependent insulinotropic polypeptide (also known as gastric inhibitory peptide [GIP]), in compensatory ß-cell hypersecretion during insulin-resistant states and in transition to ß-cell failure in type 2 diabetes is unknown.

RESEARCH DESIGN AND METHODS—We carried out oral glucose tolerance testing followed by blood sampling 10 times for 2 h on 68 age- and BMI-matched participants of the Baltimore Longitudinal Study on Aging (BLSA) with normal glucose tolerance (34 subjects), impaired glucose tolerance (IGT) (18 subjects with both impaired fasting and 2-h plasma glucose levels), and type 2 diabetes (16 subjects with both diabetic fasting and 2-h plasma glucose levels). We assayed plasma glucose, insulin, C-peptide, glucagon, and intact and total GIP levels and quantitated glucose and hormone responses to the oral glucose tolerance test. We also compared GIP and insulin release and sensitivity indexes between groups.

RESULTS—After glucose ingestion, subjects with IGT had both hyperinsulinemia and hyperemia, while subjects with type 2 diabetes had both ß- and GIP-cell deficiency. In the former group, there was also a significant positive correlation between the augmented plasma intact and total GIP levels and both fasting and post-oral glucose load plasma insulin levels.

CONCLUSIONS— Elevated plasma GIP levels are correlated with hyperinsulinemia in the impaired glucose-tolerant state, whereas type 2 diabetes is associated with a failure to secrete adequate amounts of both GIP and insulin, indicating a common pathway of resistance to and eventually failure of glucose responsiveness in ß- and GIP-cells.

Abbreviations: AUC, area under the curve • BLSA, Baltimore Longitudinal Study on Aging • GIP, glucose-dependent insulinotropic polypeptide • GLP-1, glucagon-like peptide-1 • IGT, impaired glucose tolerance • OGTT, oral glucose tolerance test


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Eur J EndocrinolHome page
J. Vrbikova, M. Hill, B. Bendlova, T. Grimmichova, K. Dvorakova, K. Vondra, and G. Pacini
Incretin levels in polycystic ovary syndrome
Eur. J. Endocrinol., August 1, 2008; 159(2): 121 - 127.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
D. Q. Pham, A. Nogid, and R. Plakogiannis
Sitagliptin: A novel agent for the management of type 2 diabetes mellitus
Am. J. Health Syst. Pharm., March 15, 2008; 65(6): 521 - 531.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
H.-J. Jang, Z. Kokrashvili, M. J. Theodorakis, O. D. Carlson, B.-J. Kim, J. Zhou, H. H. Kim, X. Xu, S. L. Chan, M. Juhaszova, et al.
Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1
PNAS, September 18, 2007; 104(38): 15069 - 15074.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
J. Zhou, M. F. A. Livak, M. Bernier, D. C. Muller, O. D. Carlson, D. Elahi, S. Maudsley, and J. M. Egan
Ubiquitination is involved in glucose-mediated downregulation of GIP receptors in islets
Am J Physiol Endocrinol Metab, August 1, 2007; 293(2): E538 - E547.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. J. Theodorakis, O. Carlson, S. Michopoulos, M. E. Doyle, M. Juhaszova, K. Petraki, and J. M. Egan
Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP
Am J Physiol Endocrinol Metab, March 1, 2006; 290(3): E550 - E559.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2004 by the American Diabetes Association.